Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Geoffrey R. Oxnard(Foundation Medicine (United States)), Vincent A. Miller(Universidad San Carlos), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Camelia S. Sima(Memorial Sloan Kettering Cancer Center), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), William Pao(Albany Medical Center Hospital), Juliann Chmielecki(Memorial Sloan Kettering Cancer Center), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Mark G. Kris(Memorial Sloan Kettering Cancer Center)
Cited by 624
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k